In line with previous studies on screening for CeD among high-risk groups, we demonstrate here that the diagnostic performance of DGP-IgG antibodies in the mass screening of the general population is higher than that of the DGP-IgA and conjugate TTG/DGP assays that did not add any advantage to the TTG-IgA assay. This evidence concerns the gene CD79A and cranioectodermal dysplasia.